Analyzing New Cancer Therapies: Margituximab, Selenexor, and Relugolix

This chapter delves into the latest studies on cancer treatments, specifically margituximab and selenexor, evaluating their clinical impact and approval status. It also highlights the promising role of relugolix in treating hormone-sensitive prostate cancer, examining its safety profile compared to conventional therapies.